Seborrheic infantile dermatitis
Methodology & AI Transparency ⓘ
Seborrheic infantile dermatitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Seborrheic infantile dermatitis (ICD-10-CM L21.1), Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols prioritize topical retinoids/calcineurin/steroid sparing in Seborrheic infantile dermatitis (L21.1: regimens) paired with baseline and interval Affected Body Surface in Seborrheic infantile dermatitis (L21.1: Area (BSA /) assessment.
- 2 Real-world patient consensus: Federal ICD-10-CM code L21.1 categorizes Seborrheic infantile dermatitis under Dermatology: Acne, Eczema, Psoriasis & Rosacea.
- 3 Typical cash cost range: Workup highlights for Seborrheic infantile dermatitis (L21.1): topical retinoids/calcineurin/steroid sparing in Seborrheic infantile dermatitis (L21.1: regimens).
- 4 Top reported side effects / signs: Longitudinal Seborrheic infantile dermatitis monitoring tracks Affected Body Surface in Seborrheic infantile dermatitis (L21.1: Area (BSA /) toward Clear or Almost Clear (IGA 0–1) (L21.1).
Ask our AI Specialists anything about Seborrheic infantile dermatitis
What Is Seborrheic infantile dermatitis?
For patients presenting with Seborrheic infantile dermatitis (ICD-10-CM L21.1), Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols prioritize topical retinoids/calcineurin/steroid sparing in Seborrheic infantile dermatitis (L21.1: regimens) paired with baseline and interval Affected Body Surface in Seborrheic infantile dermatitis (L21.1: Area (BSA /) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Seborrheic infantile dermatitis (L21.1) center on epidermal barrier filaggrin/ceramide in Seborrheic infantile dermatitis (L21.1: disruption). targeted skin & dermatology interventions aim to normalize Affected Body Surface in Seborrheic infantile dermatitis (L21.1: Area (BSA /).
Common Symptoms & Clinical Signs
- • Presentation of Seborrheic infantile dermatitis (L21.1): persistent erythematous plaques, in Seborrheic infantile dermatitis (L21.1: scaly patches, pruritic)
- • Secondary Seborrheic infantile dermatitis clinical sign: compromised epidermal barrier in Seborrheic infantile dermatitis (L21.1: with dryness, fissuring,)
- • Symptom flares in Seborrheic infantile dermatitis correlating with Affected Body Surface in Seborrheic infantile dermatitis (L21.1: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (L21.1)
- • Functional skin & dermatology impact requiring topical retinoids/calcineurin/steroid sparing in Seborrheic infantile dermatitis (L21.1: regimens) evaluation (L21.1)
Seborrheic infantile dermatitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L21.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Affected Body Surface in Seborrheic infantile dermatitis (L21.1: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L21.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Seborrheic infantile dermatitis (L21.1: ALT (if systemic) | Within baseline reference limits (L21.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Seborrheic infantile dermatitis (L21.1: & hs-CRP) | 25(OH)D 40–65 ng/mL (L21.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Seborrheic infantile dermatitis
Treatment selection for Seborrheic infantile dermatitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Seborrheic infantile dermatitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Gold-standard blind, vehicle-controlled, multicenter comparison of two 0.025%: What a 271-Participant Study Found The commercially-available 0.025% tretinoin cream and the 0.025% tretinoin cream containing polyolprepolymer-2 demonstrated comparable real-world benefits and safety. Journal of the American Academy of Dermatology • 1998-04-15 • Randomized Controlled Trial | N = 271 | 93/100 | PMID 9555823 ↗ |
| What the Latest Evidence Really Says About Skin-applied azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit Risk of bias and imprecision limit our confidence in the evidence. The Cochrane database of systematic reviews • 2020-05-01 • Meta-Analysis | Multi-cohort | 92/100 | PMID 32356369 ↗ |
| Can This Approach Help? Inside the Latest Research on Improvement of platysma prominence with onabotulinumtoxinA: safety and real-world OnabotulinumtoxinA showed favorable tolerability and significantly improved PP severity and patient-reported outcomes in participants with moderate-to-severe PP. Journal of the American Academy of Dermatology • 2025-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39442886 ↗ |
| New Insights on Clindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% Gel for: What a 515-Participant Study Found Fixed-dose, triple-combination CAB gel was efficacious and well tolerated in participants with moderate-to-severe acne, regardless of age. Journal of drugs in dermatology : JDD • 2025-12-01 • Phase III Randomized Trial | N = 515 | 87/100 | PMID 41329145 ↗ |
| Can This Approach Help? Inside the Latest Research on HautTief Multidisciplinary Educational Program for Patients with Psoriasis or An educational program may improve HRQoL and depression status of patients with psoriasis or AD. Dermatology (Basel, Switzerland) • 2022-01-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 35533665 ↗ |
Seborrheic infantile dermatitis Patient Community & “People Like Me” Threads
Filter Seborrheic infantile dermatitis community threads and patient logs by age, biological sex, dosage, and treatment duration.